港股异动 | 同源康医药-B(02410)涨超6% 艾多替尼精准布局肺癌脑转移赛道机构料产品有望于Q3上市

智通财经07-08

智通财经APP获悉，同源康医药-B(02410)涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片(TY-9591)，用于EGFR突变非小细胞肺癌(NSCLC)脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要(LBA)...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2649393952?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-08 11:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649393952","market":"hk","top_or_hot":-1,"title":"港股异动 | 同源康医药-B(02410)涨超6%  艾多替尼精准布局肺癌脑转移赛道 机构料产品有望于Q3上市","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，同源康医药-B(02410)涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片(TY-9591)，用于EGFR突变非小细胞肺癌(NSCLC)脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要(LBA)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1464555.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 同源康医药-B(02410)涨超6%  艾多替尼精准布局肺癌脑转移赛道 机构料产品有望于Q3上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 同源康医药-B(02410)涨超6%  艾多替尼精准布局肺癌脑转移赛道 机构料产品有望于Q3上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 11:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1464555.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，同源康医药-B(02410)涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片(TY-9591)，用于EGFR突变非小细胞肺癌(NSCLC)脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要(LBA)...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1464555.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1464555.html","article_id":"2649393952","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649393952","pubTimestamp":1783481174,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，同源康医药-B涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片，用于EGFR突变非小细胞肺癌脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要口头报告形式重磅发布。国海证券发布研报称，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼，预计将于2026Q3上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","02410":"同源康医药-B","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","IPOS":"Renaissance International IPO ETF","BK4588":"碎股","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","09939":"开拓药业-B"},"translate_title":"Hong Kong stock changes | Tongyuankang Pharmaceutical-B (02410) rose by more than 6%. Idotinib accurately lays out the lung cancer brain metastasis track. Institutional products are expected to be listed in Q3","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"KCAI":1.5,"VXUS":1.5,"09939":1.5,"02410":1.5,"IPOS":1.5},"content_text":"智通财经APP获悉，同源康医药-B(02410)涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片(TY-9591)，用于EGFR突变非小细胞肺癌(NSCLC)脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要(LBA)口头报告形式重磅发布。甲磺酸艾多替尼片是同源康医药自主研发的高选择性、新一代不可逆EGFR-TKI，在前期早期临床研究中已展现出优异的颅内病灶抑制能力与安全耐受性，为肺癌脑转移患者治疗带来全新突破可能。国海证券发布研报称，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼，预计将于2026Q3上市。第三代EGFR-TKI药物针对脑转移病灶的穿透与抑制能力仍存在短板。艾多替尼是奥希替尼差异化的氘代创新产品，2026年ASCO大会公司公布了艾多替尼在EGFR突变NSCLC脑转移患者一线治疗的ESAONA研究期中分析结果，艾多替尼与奥希替尼iORR为95.5% vs 79.6%，iPFS为NR vs 17.51个月(HR=0.46)，所有预设亚组患者均可从艾多替尼治疗中显著获益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649393952","isCrawlerRequest":true}

港股异动 | 同源康医药-B(02410)涨超6% 艾多替尼精准布局肺癌脑转移赛道 机构料产品有望于Q3上市

精彩评论

港股异动 | 同源康医药-B(02410)涨超6% 艾多替尼精准布局肺癌脑转移赛道机构料产品有望于Q3上市